TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03702179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: All patients will receive durvalumab (MEDI4736) (1500mg Q4W) in combination with tremelimumab (75 mg IV Q4W) for up to 3 doses/cycles each, unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met. If a patient's weight falls to 30kg or below the patient should receive weight-based dosing equivalent to 20 mg/kg of durvalumab Q4W and 1mg/kg tremelimumab Q4W until the weight improves to \>30 kg, at which point the patient should start receiving the fixed dosing of durvalumab 1500mg plus tremelimumab 75 mg Q4W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: All patients will receive durvalumab (MEDI4736) (1500mg Q4W) in combination with tremelimumab (75 mg IV Q4W) for up to 3 doses/cycles each, unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met. If a patient's weight falls to 30kg or below the patient should receive weight-based dosing equivalent to 20 mg/kg of durvalumab Q4W and 1mg/kg tremelimumab Q4W until the weight improves to \>30 kg, at which point the patient should start receiving the fixed dosing of durvalumab 1500mg plus tremelimumab 75 mg Q4W.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy at doses of 46 Gy to the minor pelvis and 64-66 Gy to the bladder.
Study: NCT04401774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be given every 4 weeks at 480mg flat dose intravenously for one year (total of 13 nivolumab doses).
Study: NCT02180828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clotrimazole vaginal tablet
Description: 2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)
Study: NCT02469792

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic surgery
Study: NCT03307681

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White bread
Description: Toasted, with canola oil added to match for fat content of French fries (13.9 grams), as well as being matched for energy (280 kilocalories) and available carbohydrate content (33 grams) of potato treatments.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baked potato with skin
Description: Baked russet potato with canola oil added once baked to match for fat content of French fries, and also matched for the salt content of white bread (280 milligrams).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mashed potato served hot
Description: Mashed potatoes prepared from frozen, with canola oil added to match for fat content of French fries, as well as being matched for energy and available carbohydrate content of the baked potato.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fried French fries
Description: Prepared from frozen, matched for energy and available carbohydrate content of baked potato and salt content of white bread.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal skipping
Description: No food given
Study: NCT03677921

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Investigational Product (Bio-Germanium)
Description: * Ingredient: Bio-Germanium~* Type: HPMC capsule~* Weight: 300mg/capsule~* Directions: 2 capsules, twice a day (1.2g/day of Bio-Germanium)~* Storage: Room temperature (below 25℃)~* Duration of use: 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control Group - Placebo Product
Description: * Ingredient: Corn starch~* Type: HPMC capsule~* Weight: 300mg/capsule~* Directions: 2 capsules, twice a day~* Storage: Room temperature (below 25℃)~* Duration of use: 8 weeks
Study: NCT00926328

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triclosan, fluoride
Description: Six Month study, brush twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride
Description: twice daily usage
Study: NCT04194580

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phisical activity intervention
Description: The prevalence of overweight in chilean children in the among the highest in the world and increasing quickly. The investigators recently evaluated an after-school program of recreational physical activity to control overweight, obesity and other cardiovascular risk factors in primary school children Temuco. This program reduced adiposity and increased the fitness.
Study: NCT02180828

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: 2 doses of 150 mg oral Fluconazole (at day1 and day4)
Study: NCT01364649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Vortioxetine tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram tablets
Study: NCT02469792

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraarticular administration of autologous ADRC
Study: NCT01364649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Vortioxetine Placebo-matching capsules
Study: NCT00903396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palonosetron hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palonosetron hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given IV
Study: NCT04018196

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motor imagery as training manual task
Description: They will have a motor imagery as training manual task for 30 minutes. They will have 3 tests for performing manual task before training (pretest) and after training (post-test).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motor imagery as training motor task
Description: They will have a motor imagery as training motor task for 30 minutes before performing this task.~They will have 3 tests for performing motor task before training (pretest) and after training (post-test).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: emotionally neutral film as training of manual task
Description: They will have to watch an emotionally neutral as training manual task for 30 minutes before performing this task.~They will have 3 tests for performing manual task before training (pretest) and after training (post-test).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: emotionally neutral film as training of motor task
Description: They will have to watch an emotionally neutral as training motor task for 30 minutes before performing this task.~They will have 3 tests for performing motor task before training (pretest) and after training (post-test).
Study: NCT04291872

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glass -Ionomer Cement with /without Led Light Cure
Description: Teeth were restored as same protocole with non-Heated Group. LED light (GC- D-Light DUO) was used at standard mode 1200 mW/cm2, at 50-60 ºC, for 60 sec.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glass -Ionomer Cement with /without Led Light Cure
Description: Teeth were restored as same protocole with non-Heated Group. LED light (GC- D-Light DUO) was used at standard mode 1200 mW/cm2, at 50-60 ºC, for 60 sec.
Study: NCT00613782

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reandron 1000
Description: 1000mg at 0,6,18,30 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo injection 0,6.18.30 weeks
Study: NCT03346616

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Texting Group
Description: See above in arm/group description

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non Texting Group
Description: See above in arm/group description
Study: NCT06044467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-human CCL24 monoclonal antibody (CM-101) - Part One
Description: Anti-human CCL24 monoclonal antibody (CM-101) - Part One

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-human CCL24 monoclonal antibody (CM-101) - Part Two
Description: Anti-human CCL24 monoclonal antibody (CM-101) - Part Two
Study: NCT03868410

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: New rTMS Approach
Description: Participants in this arm will receive rTMS-based facilitation of the contralesional dorsal premotor cortex (cPMd) located in the non-stroke hemisphere before start of each session. High-frequency rTMS (5-Hz) will be delivered using 42 10-sec trains of 50 pulses each (total 2100 pulses) for a period of 24 minutes. Immediately after the completion of rTMS, participants will undergo upper limb training for a total of one hour. Participants will receive these interventions 2 days a week for 6 weeks, i.e., for a total of 12 sessions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rTMS Approach
Description: Participants in this arm will receive rTMS-based facilitation of the ipsilesional primary motor cortex (iM1) before the start of each session. iM1 will be stimulated with high-frequency rTMS (5-Hz) using 42 10-sec trains of 50 pulses each (total 2100 pulses) for a period of 24 minutes. Immediately after the completion of rTMS, participants will undergo upper limb training for a total of one hour. Participants will receive these interventions 2 days a week for 6 weeks, i.e., for a total of 12 sessions.
Study: NCT00765440

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: therapeutic nutritional supplementation
Description: Given orally

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: therapeutic nutritional supplementation
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given orally
Study: NCT00697658

Intervention type: DRUG
Intervention: Paliperidone ER
Description: 6 mg tablet once daily, variable treatment length.
Study: NCT01653158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-751,871
Description: CP-751,871 was given intravenously \[IV\] every 3 weeks in escalating doses ranging from 0.1 mg/kg up to 20 mg/kg.~Standard doses of Docetaxel were given every 3 weeks with CP-751,871. Study therapy was continued until disease progression, lack of tolerability for up to 17 cycles (approximately 1 year).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel up to 75 mg/m\^2 was administered intravenously \[IV\] on Day 1 of each 3-week dosing cycle.
Study: NCT02999568

Intervention type: OTHER
Intervention: Physical exercise
Description: Women who practice high level of physical activity, as defined by International Physical Activity Questionnaire, for the past 3 years will be recruited. These women will will be asked to fulfill the International Physical Activity Questionnaire and additional questionnaire regarding relevant demographic and medical information. Blood samples to anti-mullerian hormone , leptin, and hormonal profile will be obtained in day 3 of menstruation. Ultrasound will be performed to measure Antral Follicular count and ovarian blood flow
Study: NCT04777214

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Active TMS will be at 90% motor threshold

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TMS
Description: Sham TMS will be administered
Study: NCT01671722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast sodium
Description: Montelukast sodium tablets 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast sodium
Description: Montelukast sodium tablets 10mg
Study: NCT01191905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose CRRT
Description: clearance of 80 mL/Kg/hr (1:1 balanced pre-dilution CVVHDF)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional dose CRRT
Description: clearance of 40 mL/Kg/hr (1:1 balanced pre-dilution CVVHDF)
Study: NCT04441736

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: High flow nasal cannula
Description: Device gives high flow oxygen comparable to non invasive ventilation and conventional oxygen therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High flow nasal cannula
Description: Device gives high flow oxygen comparable to non invasive ventilation and conventional oxygen therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High flow nasal cannula
Description: Device gives high flow oxygen comparable to non invasive ventilation and conventional oxygen therapy
Study: NCT01359956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: 900 mg / m2 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: 900 mg / m2 every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: 900 mg / m2 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: 900 mg / m2 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fotemustine
Description: 100 mg / m2 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fotemustine
Description: 100 mg / m2 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Alfa-2b
Description: 5 M units every 3 weeks
Study: NCT03499002

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulated Learning Environment
Description: Intervention is the environment in which the medical student will learn to practice how to suture. The end goal is to determine the impact each environment has on their ability to learn the skill.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulated Learning Environment
Description: Intervention is the environment in which the medical student will learn to practice how to suture. The end goal is to determine the impact each environment has on their ability to learn the skill.
Study: NCT02486211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine
Description: 100mg twice per day for 7 days at 0600 and 1200

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT02673879

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pericardiocentesis with Alteplase
Description: Complete percutaneous pericardial drainage facilitated by intrapericardial alteplase

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Pericardiocentesis
Description: Conventional pericardiocentesis when indicated
Study: NCT00686582

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMVAMUNE
Description: 1x 10E8_TCID50

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMVAMUNE
Description: 1x 10E8_TCID50

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood Draw Only
Study: NCT02814435

Intervention type: OTHER
Intervention: Questionnaire
Description: The participants will answer two questionnaires. These are the NEI VFQ-25 and the DLTV (daily living tasks of vision).
Study: NCT01359956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Alfa-2b
Description: 5 M units every 3 weeks
Study: NCT00797069

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard nutritional product (medical food)
Description: once during crossover
Study: NCT00903396

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given IV
Study: NCT00989560

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopy
Description: patients receive best treatment and care with an additional endoscopy
Study: NCT03119831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol-based Chlorhexidine Gluconate 0.12%
Description: Rinsing with 15ml for one minute twice daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol-free Chlorhexidine Gluconate 0.12%
Description: Rinsing with 15ml for one minute twice daily for 14 days
Study: NCT02814435

Intervention type: OTHER
Intervention: Questionnaire
Description: The participants will answer two questionnaires. These are the NEI VFQ-25 and the DLTV (daily living tasks of vision).

Intervention type: OTHER
Intervention: Computerised contrast sensitivity function test
Description: This test involves the patient identifying whether bars on a screen are horizontal or vertical. It is designed to measure contrast sensitivity.

Intervention type: OTHER
Intervention: Computerised contrast sensitivity function test
Description: This test involves the patient identifying whether bars on a screen are horizontal or vertical. It is designed to measure contrast sensitivity.
Study: NCT00797069

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nutritional product for diabetes (medical food)
Description: once during crossover

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diabetes specific experimental nutritional product (medical food)
Description: once during crossover
Study: NCT00987922

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypothermia
Description: Hypothermia to core temperature of 35C for 12 hours, rewarming rate 0.2C until the patient reaches 36.8C
Study: NCT04417504

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MobFood breakfast kit
Description: Cereal biscuit with orange fruit, cheese with fruit preparation and beverage based on oat, milk and mocha (without added sugar), specifically developed for the project MobFood_PPS4.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control isocaloric breakfast
Description: White bread, butter and milk.
Study: NCT02995330

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation
Description: Infused with non-T-cell depleted bone marrow from a related female donor on Day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoxan
Description: Cytoxan 50mg/kg IV on Days +3 and +4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone cypionate
Description: testosterone cypionate 400 mg IM will be administered on Day +60, +90, and +120 (every 30 days x 3 doses)
Study: NCT01054976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine
Description: Orally administered Galantamine 8 mg/day for the first 4 weeks. Thereafter the dose will be increased to 16 mg/day. If tolerated, the dose of galantamine can be increased up to 24 mg/day.
Study: NCT04032626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide 10 mg
Description: Lenalid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05412537

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MI
Description: How to motivate people

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CAU
Description: consult as usual
Study: NCT01098461

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: albiglutide
Description: subcutaneous injection of albiglutide
Study: NCT00710593

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HPV vaccine for strains -6, -11, -16, and -18
Description: All subjects will receive three doses of the HPV-6, -11, -16, -18 vaccine at the recommended dose and schedule (Day 0, Week 8, and Week 24).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HPV vaccine for strains -6, -11, -16, and -18
Description: All subjects will receive three doses of the HPV-6, -11, -16, -18 vaccine at the recommended dose and schedule (Day 0, Week 8, and Week 24).
Study: NCT00525421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcuminoids
Description: Curcuminoids tablets 2000mg three times per day for 12 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03496116

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECIG Session
Description: Participants will complete four sessions using an e-cigarette, including a 10-puff product use bout followed by a 60-minute ad lib bout over an approximately 4-hour period. The study conditions for each session (i.e., heater resistance and nicotine combinations) will be Latin-square ordered.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECIG Session
Description: Participants will complete four sessions using an e-cigarette, including a 10-puff product use bout followed by a 60-minute ad lib bout over an approximately 4-hour period. The study conditions for each session (i.e., heater resistance and nicotine combinations) will be Latin-square ordered.
Study: NCT01098461

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: albiglutide
Description: subcutaneous injection of albiglutide

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: albiglutide
Description: subcutaneous injection of albiglutide

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous injection of placebo to match albiglutide
Study: NCT04428359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Measles-Mumps-Rubella Vaccine
Description: Group A patients will receive intralesional injection of upto 0.5 mL of reconstituted MMR vaccine into a single or a maximum of 5 warts at a time in case of multiple warts. Intralesional injection will be given every three weeks for a maximum of 5 doses or until complete resolution, whichever is earlier.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vit D
Description: Group B patients will receive a maximum of 0.5 mL Inj. Vitamin D3 (600,000 IU; 15mg/ml) in each session after injection of IL lignocaine with 31 G insulin syringe. In cases of multiple warts, a maximum of 5 warts will be injected at a time. The session will be done at 3 weekly intervals for a maximum of 5 sessions or until complete resolution of warts, whichever is earlier